Evaluation of Dose–Response Relationship in Novel Extended Release of Targeted Nucleic Acid Nanocarriers to Treat Secondary Cataracts
Journal of Ocular Pharmacology and Therapeutics · 01.09.2024 · 40 (7) · 459-466
DOI: 10.1089/jop.2024.0024 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Ocular Pharmacology and Therapeutics, erschienen am 01.09.2024. Verfasst von Camila Vardar und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, Rowan Virtua School of Translational Biomedical Engineering and Sciences University, Glassboro, New Jersey, USA. Hauptthemen laut MEDLINE: Doxorubicin, Delayed-Action Preparations, Dose-Response Relationship, Drug, Drug Carriers. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 53 Literaturangaben.
Abstract (Originalsprache)
Purpose
The present study aimed to determine the dose-response relationship between targeted nanocarriers released from a novel, sustained release formulation and their ability to specifically deplete cells responsible for the development of posterior capsular opacification (PCO) in month-long, dynamic cell cultures.
Methods
Injectable, thermosensitive poly(D,L-lactic-co-glycolic acid)-b-poly(ethylene glycol)-b-poly(D,L-lactic-co-glycolic acid) triblock copolymer hydrogels were loaded with either a low or a high dose of doxorubicin-loaded antibody-targeted nanocarriers (G8:3DNA:Dox). Human rhabdomyosarcoma cells, selected for their expression of PCO marker brain-specific angiogenesis inhibitor 1 (BAI1), were kept under dynamic media flow and received either a low or high dose of nanocarriers. Cells were fixed and stained at predetermined time points to evaluate targeted depletion of BAI1+ cells.
Results
A lower dose of nanocarriers in hydrogel depleted BAI1+ cells at a slower rate than the higher dose, whereas both reached over 90% BAI1+ cellular nonviability at 28 days. Both treatment groups also significantly lowered the relative abundance of BAI1+ cells in the population compared with the control group.
Conclusions
Controlled release of a lower dose of nanocarriers can still achieve therapeutically relevant effects in the prevention of PCO, while avoiding potential secondary effects associated with the administration of a higher dose.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Engineering, Rowan Virtua School of Translational Biomedical Engineering and Sciences University, Glassboro, New Jersey, USA.
- Philadelphia College of Osteopathic Medicine, Philadelphia, Pennsylvania, USA.
- Genisphere, LLC, Hatfield, Pennsylvania, USA.
- OcuMedic, Inc., Mullica Hill, New Jersey, USA.
- Department of Chemical Engineering, Rowan University, Glassboro, New Jersey, USA.
ORCID-Profile: Camila Vardar, Mark E Byrne
Zitieren
APA
Vardar, C., George-Weinstein, M., Getts, R., & Byrne, M. E. (2024). Evaluation of Dose–Response Relationship in Novel Extended Release of Targeted Nucleic Acid Nanocarriers to Treat Secondary Cataracts. Journal of Ocular Pharmacology and Therapeutics, 40(7), 459-466. https://doi.org/10.1089/jop.2024.0024
Vancouver
Vardar C, George-Weinstein M, Getts R, Byrne ME. Evaluation of Dose–Response Relationship in Novel Extended Release of Targeted Nucleic Acid Nanocarriers to Treat Secondary Cataracts. Journal of Ocular Pharmacology and Therapeutics. 2024;40(7):459-466. doi:10.1089/jop.2024.0024
BibTeX
@article{Vardar2024,
author = {Vardar, Camila and George-Weinstein, Mindy and Getts, Robert and Byrne, Mark E},
title = {Evaluation of Dose–Response Relationship in Novel Extended Release of Targeted Nucleic Acid Nanocarriers to Treat Secondary Cataracts},
journal = {Journal of Ocular Pharmacology and Therapeutics},
year = {2024},
volume = {40},
number = {7},
pages = {459--466},
doi = {10.1089/jop.2024.0024}
}
EUVIMED